- Home
- IPHA vs CABA Comparison
IPHA vs CABA Comparison
Compare IPHA & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- CABA
- Stock Information
- Founded
- IPHA 1999
- CABA 2017
- Country
- IPHA France
- CABA United States
- Employees
- IPHA N/A
- CABA N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IPHA Health Care
- CABA Health Care
- Exchange
- IPHA Nasdaq
- CABA Nasdaq
- Market Cap
- IPHA 150.9M
- CABA 118.8M
- IPO Year
- IPHA 2019
- CABA 2019
- Fundamental
- Price
- IPHA $1.95
- CABA $2.29
- Analyst Decision
- IPHA Strong Buy
- CABA Strong Buy
- Analyst Count
- IPHA 1
- CABA 9
- Target Price
- IPHA $11.50
- CABA $27.22
- AVG Volume (30 Days)
- IPHA 50.9K
- CABA 1.4M
- Earning Date
- IPHA 03-20-2025
- CABA 03-20-2025
- Dividend Yield
- IPHA N/A
- CABA N/A
- EPS Growth
- IPHA N/A
- CABA N/A
- EPS
- IPHA N/A
- CABA N/A
- Revenue
- IPHA $36,202,722.00
- CABA N/A
- Revenue This Year
- IPHA N/A
- CABA N/A
- Revenue Next Year
- IPHA $101.65
- CABA N/A
- P/E Ratio
- IPHA N/A
- CABA N/A
- Revenue Growth
- IPHA N/A
- CABA N/A
- 52 Week Low
- IPHA $1.29
- CABA $1.76
- 52 Week High
- IPHA $3.51
- CABA $26.35
- Technical
- Relative Strength Index (RSI)
- IPHA 56.50
- CABA 45.76
- Support Level
- IPHA $1.72
- CABA $2.20
- Resistance Level
- IPHA $1.92
- CABA $2.48
- Average True Range (ATR)
- IPHA 0.11
- CABA 0.22
- MACD
- IPHA 0.02
- CABA 0.02
- Stochastic Oscillator
- IPHA 89.74
- CABA 33.78
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.